Plasma metabolomics of immune-related adverse events for patients with lung cancer treated with PD-1/PD-L1 inhibitors
Plasma-Metabolomik immunbezogener unerwünschter Ereignisse bei Patient:innen mit Lungenkrebs unter PD-1/PD-L1-Inhibitoren
Journal for ImmunoTherapy of Cancer · 2024-07 · 12 (7) · e009399
DOI: 10.1136/jitc-2024-009399 ↗Auf einen Blick
Bei 85 Patient:innen mit Lungenkrebs unter PD-1/PD-L1-Inhibitoren unterschieden sich 24 Metabolite zwischen Personen mit und ohne irAEs. Ein Basismodell aus 8 Acylcarnitinen und 6 Steroiden sagte irAEs mit AUC 0,91 vorher.
Fragestellung
Welche Plasma-Metabolite sind mit dem Auftreten von irAEs und mit dem Überleben bei Patient:innen mit Lungenkrebs unter PD-1/PD-L1-Inhibitoren assoziiert?
Methode
Analyse von 170 Plasma-Proben von 85 Patient:innen mit Lungenkrebs; untargeted Metabolomik vor Therapiebeginn und bei irAEs, Kaplan-Meier-Analyse zum Überleben.
Ergebnisse
24 differentielle Metabolite zur Vorhersage von irAEs. Baseline-Acylcarnitine und -Steroide waren bei irAEs höher; das Modell aus 8 Acylcarnitinen und 6 Steroiden hatte eine AUC von 0,91. Niedrigere Baseline-Decenoylcarnitine und Hexanoylcarnitine waren mit besserem OS assoziiert.
Schlussfolgerung der Autor:innen
Hohe Acylcarnitin- und Steroidhormonspiegel könnten Risikofaktoren für irAEs sein; Decenoylcarnitine und Hexanoylcarnitine könnten das OS vorhersagen.
Kernaussagen
- 24 Metabolite unterschieden sich zur Vorhersage von irAEs
- AUC 0,91 für ein Basismodell aus 8 Acylcarnitinen und 6 Steroiden
- Niedrige Decenoylcarnitin- und Hexanoylcarnitin-Spiegel waren mit besserem OS assoziiert
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 11.07.2024. Verfasst von Juan Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China. Hauptthemen laut MEDLINE: Lung Neoplasms, Immune Checkpoint Inhibitors, Metabolomics. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Hunan province key research and development plan of china, National Natural Science Foundation of China, Changsha Municipal Natural Science Foundation.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Metabolomics has the characteristics of terminal effects and reflects the physiological state of biological diseases more directly. Several current biomarkers of multiple omics were revealed to be associated with immune-related adverse events (irAEs) occurrence. However, there is a lack of reliable metabolic biomarkers to predict irAEs. This study aims to explore the potential metabolic biomarkers to predict risk of irAEs and to investigate the association of plasma metabolites level with survival in patients with lung cancer receiving PD-1/PD-L1 inhibitor treatment.
Methods
The study collected 170 plasmas of 85 patients with lung cancer who received immune checkpoint inhibitors (ICIs) treatment. 58 plasma samples of 29 patients with irAEs were collected before ICIs treatment and at the onset of irAEs. 112 plasma samples of 56 patients who did not develop irAEs were collected before ICIs treatment and plasma matched by treatment cycles to onset of irAEs patients. Untargeted metabolomics analysis was used to identify the differential metabolites before initiating ICIs treatment and during the process that development of irAEs. Kaplan-Meier curves analysis was used to detect the associations of plasma metabolites level with survival of patients with lung cancer.
Results
A total of 24 differential metabolites were identified to predict the occurrence of irAEs. Baseline acylcarnitines and steroids levels are significantly higher in patients with irAEs, and the model of eight acylcarnitine and six steroid metabolites baseline level predicts irAEs occurrence with area under the curve of 0.91. Patients with lower concentration of baseline decenoylcarnitine(AcCa(10:1) 2, decenoylcarnitine(AcCa(10:1) 3 and hexanoylcarnitine(AcCa(6:0) in plasma would have better overall survival (OS). Moreover, 52 differential metabolites were identified related to irAEs during ICIs treatment, dehydroepiandrosterone sulfate, corticoserone, cortisol, thyroxine and sphinganine 1-phaosphate were significantly decreased in irAEs group while oxoglutaric acid and taurocholic acid were significantly increased in irAEs group.
Conclusions
High levels of acylcarnitines and steroid hormone metabolites might be risk factor to development of irAEs, and levels of decenoylcarnitine (AcCa(10:1) 2, decenoylcarnitine (AcCa(10:1) 3 and hexanoylcarnitine (AcCa(6:0) could be used to predict OS for patients with lung cancer received ICIs treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.
- Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, and National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republi…
- Department of Pharmacy, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China.
- Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.
- National Institution of Drug Clinical Trial, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.
- Department of Physiology, School of Basic Medical Sciences, Shandong University, Jinan, Shandong, People's Republic of China.
ORCID-Profile: Zhaoqian Liu
Förderung
- Hunan province key research and development plan of china
- National Natural Science Foundation of China
- Changsha Municipal Natural Science Foundation
- Natural Science Foundation of Hunan Province
- Major Project of natural science foundation of Hunan Province
- China Postdoctoral Science Foundation
Zitieren
APA
Chen, J., Liu, J. S., Liu, J. Y., She, L., Zou, T., Yang, F., Li, X. P., Wang, Z., & Liu, Z. (2024). Plasma metabolomics of immune-related adverse events for patients with lung cancer treated with PD-1/PD-L1 inhibitors. Journal for ImmunoTherapy of Cancer, 12(7), e009399. https://doi.org/10.1136/jitc-2024-009399
Vancouver
Chen J, Liu JS, Liu JY, She L, Zou T, Yang F, et al. Plasma metabolomics of immune-related adverse events for patients with lung cancer treated with PD-1/PD-L1 inhibitors. Journal for ImmunoTherapy of Cancer. 2024;12(7):e009399. doi:10.1136/jitc-2024-009399
BibTeX
@article{Chen2024,
author = {Chen, Juan and Liu, Jia-Si and Liu, Jun-Yan and She, Lei and Zou, Ting and Yang, Fan and Li, Xiang-Ping and Wang, Zhan and Liu, Zhaoqian},
title = {Plasma metabolomics of immune-related adverse events for patients with lung cancer treated with PD-1/PD-L1 inhibitors},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
volume = {12},
number = {7},
pages = {e009399},
doi = {10.1136/jitc-2024-009399}
}
EUVIMED